GeneNews is Now StageZero Life Sciences
On June 19, 2019 GeneNews received shareholder approval to change the company name to StageZero Life Sciences. The new ticker symbol is now (TSX: SZLS). We are excited to embark on this exciting journey to reduce late stage cancers through early detection and bring to market our next-generation blood test for simultaneously screening for 10 cancers from a single sample of blood.
We are StageZero Life Sciences and we are dedicated to finding cancer in the earliest stages when it is most curable. Our next-generation test, Aristotle™, is a panel for simultaneously screening for 10 cancers from a single blood sample. Aristotle has been built on the company's mRNA Sentinel Principle Technology Platform, which was used to develop one of the first commercially available blood tests for Colorectal Cancer, ColonSentry®.
Investor Relations Contacts
James R. Howard-Tripp
Chairman and CEO
Financial Communication Advisor
30-70 East Beaver Creek Road
Richmond Hill, ON L4B 3B2
Stay In Touch! Subscribe to Our Investor Updates